Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Phio Pharmaceuticals Corp. on February 13, 2023, covering events occurring on February 9, 2023. The Company is incorporated in Delaware and its common stock trades on The NASDAQ Capital Market under the symbol "PHIO".
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing status events.
Material Changes
- Regained Nasdaq Compliance: On February 9, 2023, the Company received written notice from The Nasdaq Stock Market LLC confirming it has regained compliance with the minimum bid price requirement (Listing Rule 5550(a)(2)).
- Reverse Stock Split: Compliance was achieved following a one-for-twelve reverse split of the Company's common stock, which became effective on January 26, 2023.
Outlook, Risks, and Management Commentary
Management commentary is limited to the confirmation of regained listing compliance. The filing references a prior Form 8-K filed on January 25, 2023, for additional details regarding the reverse split. No new risks, contingencies, or financial guidance are disclosed in this specific document.
Investor Verification Checklist
- Verify the effective date of the one-for-twelve reverse stock split (January 26, 2023).
- Confirm the current trading status of PHIO on The NASDAQ Capital Market.
- Review the January 25, 2023 Form 8-K for detailed terms of the reverse split.
- Check subsequent filings for updated financial performance post-split.